INTRODUCTION
In anaerobes, pyruvate: ferredoxin oxidoreductase (pyruvate synthase, EC 1.2.7.1) catalyses the CoA-and ferredoxindependent oxidative decarboxylation of pyruvate (Buchanan, 1972) (Reed, 1974; Kerscher & Oesterhelt, 1982; Perham et al., 1987; Williams et al., 1987) . However, both pyruvate: ferredoxin oxidoreductase and El contain thiamin pyrophosphate (TPP) as the cofactor involved in pyruvate decarboxylation, suggesting similarities in the initial steps of the catalytic cycle.
The catalytic mechanism of pyruvate: ferredoxin oxidoreductase has not been unequivocally elucidated, and several alternative mechanisms have been proposed, depending on whether electrons are removed individually from the initial decarboxylation product (Kerscher & Oesterhelt, 1981a,b; Docampo et al., 1987) , or in one step (Wahl & Orme-Johnson, 1987) , as in the pyruvate dehydrogenase complex.
In the important human protozoan parasite Trichomonas vaginalis pyruvate:ferredoxin oxidoreductase plays an essential role in anaerobic energy production from pyruvate (Muller, 1988) . It is also the enzyme responsible for the activation of the widely used anti-trichomonal drug metronidazole (Chapman et al., 1985) . To aid rational design of drugs against the T. vaginalis pyruvate:ferredoxin oxidoreductase, we were interested in obtaining a better understanding of the active site of the enzyme and finding differences between it and its host counterpart, the pyruvate dehydrogenase complex.
To this end, we have utilized structural analogues of pyruvate, and pyruvate itself, to study the active site of the pyruvate: ferredoxin oxidoreductase from T. vaginalis and to compare it with that of the pyruvate decarboxylase component of the pyruvate dehydrogenase complex.
EXPERIMENTAL Materials
2-Oxo acids, pyruvate analogues and coenzymes were obtained from Sigma Chemical Co., Poole, Dorset, U.K. Pyruvate: ferredoxin oxidoreductase from T. vaginalis was purified as described by Williams et al. (1987) . Pyruvate dehydrogenase multienzyme complex and its El component were isolated from Escherichia coli (Lowe & Perham, 1984) . Tetrahydro-TPP was prepared as described by Lowe et al. (1983) .
Enzyme assays
Oxidative decarboxylation of pyruvate by the pyruvate: ferredoxin oxidoreductase was measured spectrophotometrically with Methyl Viologen as electron acceptor, in the presence of an 02-scavenging system to decrease the lag phase (Williams et al., 1987) . Enzyme activities were measured from the linear steady-state rates obtained after any lag phase.
Overall pyruvate dehydrogenase complex activity was meas-pyruvate, CoA, NAD+ and TPP as described by Lowe & Perham (1984) . The enzymic activity of the El component was measured either by reconstitution with E2E3 subcomplex and measuring overall pyruvate dehydrogenase complex activity, or by assay of pyruvate decarboxylase activity after the enzyme-catalysed reduction of the dye 2,6-dichlorophenolindophenol by pyruvate in the absence of CoA (Lowe & Perham, 1984) . The enzyme activity of the El component was dependent on the presence of TPP in the assay. Irreversible inhibition was measured by preincubating enzyme and inhibitor, and then assaying samples at various time intervals by dilution into the standard assay mixtures. The preincubation reaction mixture for pyruvate: ferredoxin oxidoreductase activity consisted of 20 mM-Tris/HCI, pH 7.0, and 0.4 M-KCI. The preincubation reaction mixture for El consisted of 50 mM-potassium phosphate buffer, pH 7, 1 mM-MgCl2 and 0.2 mM-TPP. Control experiments were carried out to check that no significant loss of activity of untreated enzyme occurred.
RESULTS

Inhibition by pyruvate
Preincubation of pyruvate: ferredoxin oxidoreductase with 1 mM-pyruvate at 4°C resulted in a time-dependent inactivation of the enzyme activity as measured by extensive dilution into assay medium (Fig. 1) . The inhibited assay traces were linear, suggesting that the inhibition was irreversible on the time scale of the assay.
The inactivation induced by pyruvate was partially prevented by prior addition of dithiothreitol to the enzyme, but dithiothreitol did not reverse inhibition by pyruvate that had already occurred (Fig. 1) . Over 60 min incubation at 20°C the enzyme loses 190% of activity (Table 1) . This loss can be decreased by including dithiothreitol in the incubation medium. A slightly larger loss occurs in the presence of the oxygen-scavenging The inhibition was not reversed by treatment of inactivated enzyme with 0.2 M-hydroxylamine, pH 7, for 30 min at 20°C, conditions which did not affect the activity of control enzyme untreated with pyruvate. This suggested that a thioester was not involved in the inhibition. Furthermore, incubation with 2 mMacetoin for 60 min at 20°C did not result in any inhibition, demonstrating that this potential enzymic product was also not the cause of the pyruvate-induced inhibition.
We found that the activity of pyruvate: ferredoxin oxidoreductase was not affected by incubation of the enzyme for 30 min at 4°C with 1 mM-5,5'-dithiobis-(2-nitrobenzoic acid), 1 mM-iodoacetic acid, 1 mM-iodoacetamide, 1 mM-N-ethylmale- (Fig. 2a) . The inhibition of El activity was not related to reductive acetylation of lipoate residues, since a similar rate of inhibition was seen with intact complex and with its isolated El component (results not shown), and the inhibition of the activity of isolated El was the same whether inhibition was measured by reconstitution with E2/E3 subcomplex or by dichlorophenolindophenol reduction (Fig.  2a) . The inhibition was completely dependent on the inclusion of TPP in the preincubation medium (Fig. 2b) .
As with pyruvate: ferredoxin oxidoreductase, the inhibition of El activity could be prevented by exclusion of 02 from the medium, or by the presence of mercaptoethanol, and was not reversed by addition of mercaptoethanol to pyruvate-inhibited enzyme (Fig. 2c) . A further similarity was the unusual dependence on pyruvate concentration (Fig. 2b) (Lowe & Perham, 1984; Apfel et al., 1984) , though the high reactivity of the a-haloketone group makes it a candidate as a non-selective alkylating agent. However, preincubation of pyruvate: ferredoxin oxidoreductase with I mM-bromopyruvate for 60 min did not result in any time-dependent irreversible inhibition, although it did have an inhibitory effect. When samples were assayed by dilution into assay medium which did not contain dithiothreitol, a considerable lag period was observed before a linear, yet inhibited, assay rate was seen. This lag could be many minutes at high bromopyruvate concentrations ( Fig. 3 and Table 3 ). If, however, the samples were assayed in the presence of dithiothreitol, the observed rate was linear and uninhibited as soon as the short lag phase was over, i.e. the progress curve was the same as that for an incubation which did not contain bromopyruvate. Assays in which bromopyruvate was added directly to assays and then the reaction was initiated by adding enzyme (Fig. 3) indicated that the extended lag phase and inhibited rate was due to carry-over of bromopyruvate present in the preincubation. Again, both the inhibition of the linear rate and the extended lag phase were prevented by the presence of dithiothreitol in the assay, presumably owing to destruction of the bromoacyl moiety by reaction with the thiol groups of dithiothreitol. Thus this inhibition was of a reversible rather than an irreversible nature.
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Thus at 20 /tM-bromopyruvate in the presence of200 4aM-pyruvate the enzyme was inhibited 960, whereas at 2 mM-pyruvate the inhibition was only 180% (Table 3) . This suggested that the inhibition was reversible and at or near the pyruvate-binding site.
Since bromopyruvate can react rapidly with the thiol groups of CoA, which is present as substrate in the assay mixture, experiments were carried out to establish the nature of the inhibitory species. Prior addition of dithiothreitol prevented any effect of bromopyruvate on the lag phase or any inhibition of enzyme activity, presumably by covalent reaction with bromopyruvate (results not shown). However, if dithiothreitol was added to an assay during the extended lag phase caused by bromopyruvate, the progress curve was the same as if dithiothreitol had not been added. In particular, the linear reaction rate seen after the lag was inhibited to the same extent as if dithiothreitol had not been added (Fig. 3) . These data suggest that neither bromopyruvate itself nor an adduct between dithiothreitol and bromopyruvate is the cause of the inhibition by bromopyruvate of the linear reaction rate (see the Discussion section).
Bromopyruvate (100 /uM or 1 mM) was allowed to react completely with 1 mM-CoA or 100 ,M-CoA respectively, so that two mixtures were obtained both containing 100 ,tM of a CoA adduct with bromopyruvate but with one containing additionally 900 ,uM-bromopyruvate and the other 900 ,tM-CoA. A 100 1l sample of each was then added to an assay containing enzyme, 2 mM-pyruvate and either 56 ,tM-CoA or 146 /LM-CoA. For both assays the same lag phase and inhibited rate was seen, strongly suggesting that the inhibitory species is the adduct of CoA and bromopyruvate.
Inhibition by hydroxypyruvate Surprisingly, hydroxypyruvate was a potent time-dependent irreversible inhibitor of pyruvate: ferredoxin oxidoreductase activity (Fig. 4) . In contrast, preincubation ofeither E. coli pyruvate dehydrogenase complex El component (Lowe & Perham, 1984) or yeast pyruvate decarboxylase with 1 mM-hydroxypyruvate in incubation buffer containing 0.2 mM-TPP and I mM-MgCl2 for up to 2 h at 20°C did not result in any irreversible inhibition. (Lowe et al., 1983 ).
DISCUSSION
The results described in this paper demonstrate some interesting similarities and differences between the active sites for pyruvate decarboxylation in pyruvate: ferredoxin oxidoreductase and the pyruvate dehydrogenase complex. Both enzymes are inactivated by preincubation with one of their substrates, pyruvate, and both enzymes displayed a similar unusual dependence on the concentration of pyruvate. However, only the pyruvate dehydrogenase complex is irreversibly inhibited by bromopyruvate, whereas only the pyruvate: ferredoxin oxidoreductase is irreversibly inhibited by hydroxypyruvate.
Pyruvate-induced inactivation of the pyruvate dehydrogenase complex has been reported previously from the enzyme isolated from a number of sources, including pigeon breast muscle (Khailova et al., 1983 (Khailova et al., , 1985 , pig heart (Sumegi & Alkonyi, 1983) and Bacillus stearothermophilus (Henderson, 1979) . However, different mechanisms have been proposed to account for the inactivation.
Using pigeon muscle pyruvate dehydrogenase complex, Khailova et al. (1983) found a similar concentration-dependence of inhibition on pyruvate concentration, as is reported here with bacterial complex and pyruvate: ferredoxin oxidoreductase. They proposed that pyruvate bound to TPP on the enzyme was decarboxylated in the normal way, but in the presence of low pyruvate concentrations underwent a side reaction to cause inactivation. However, at higher pyruvate concentrations, inactivation is prevented, because the intermediate reacts with a second molecule of pyruvate to produce acetolactic acid and then acetoin, faster than it undergoes the inactivating side reaction. We consider that this is a good explanation of the effects that we too have described. A similar concentration-dependence for inhibition by bromopyruvate has been reported and a similar explanation proposed for it (Lowe & Perham, 1984) .
The protective effect of thiol-containing compounds was also reported by Henderson (1979) and by Khailova et al. (1983) . However, Khailova et al. (1983) did not comment on any protective effect of excluding oxygen, and we assume that their experiments were conducted in air-saturated buffers. Khailova et al. (1985) reported that inactivation of pyruvate dehydrogenase complex by [14C]pyruvate was accompanied by incorporation of radioactivity into the protein fraction and the appearance of a new peak in the absorption spectrum of the enzyme at 235 nm. This peak was attributed to the formation of a thioester bond. They demonstrated that inactivation resulted in the covalent modification of two thiol groups per El molecule. Khailova et al. (1985) proposed that inactivation was the result of the hydroxyethyl-TPP carbanion intermediate reacting with functionally essential thiol groups to give an acetylated form of the enzyme, and dithiothreitol prevented the inactivation by acting as an alternative acetyl acceptor. No explanation was offered as to how hydroxyethyl-TPP or the acetaldehyde/thiol adduct is oxidized to acetyl-TPP or acetyl-enzyme.
There are thus substantial indications from our results that the mechanism proposed by Khailova et al. (1985) Indeed, enzyme could be obtained that was still inhibited but did not have radiolabel associated with it. This suggested that the formation of a covalent adduct between enzyme and pyruvate was not necessary for inactivation. Fourthly, inactivation could be prevented by excluding oxygen, and Khailova et al. (1985) did not propose a role for oxygen in their mechanism. A satisfactory explanation for the pyruvate-mediated inhibition seen both in our experiments and in those of Khailova et al. (1983 Khailova et al. ( , 1985 comes from the work of Sumegi & Alkonyi (1983) on pig heart pyruvate dehydrogenase complex. They found that inactivation of this complex by pyruvate was only observed in the presence of an oxidant such as dichlorophenolindophenol. The inhibition of overall complex activity was due to both inhibition of the pyruvate decarboxylase (El) and transacetylase (E2) components. These components were still inhibited after gel filtration. In contrast with the results of Khailova et al. (1983) , activity was not restored by mercaptoethanol or hydroxylamine. Although Sumegi & Alkonyi (1983) found that radioactivity from [2-14C]pyruvate was covalently incorporated into the enzyme, most of it was bound to the E2 component (at sites other than lipoic acid) and only a minor part was incorporated into El. When the inactivated complex was deproteinized, a new compound absorbing at 232 nm, which potently inhibited the activity of the El component, was found in the supernatant. This compound was proposed to be thiamin thiazolone pyrophosphate, a known potent inhibitor of El (Gutowski & Lienhard, 1976 ). Sumegi & Alkonyi (1983 proposed a plausible mechanism to account for the pyruvate-induced inhibition. The enzyme-bound hydroxyethyl-TPP carbanion can be oxidized by extrinsic oxidants such as dichlorophenolindophenol or oxygen to give a reactive intermediate, possibly acetyl-TPP, most of which is transformed to acetate and enzymebound TPP. However, once every 300 turnovers inactivation occurs as the oxidized intermediate is transformed into the inhibitor, thiamin thiazolone pyrophosphate, tightly bound at the active site of El. They further proposed that the acetyl-TPP (or equivalent) generated at the active site acetylated amino acid residues on E2, and to a lesser extent on El, accounting for an irreversible inhibition of E2 activity that they also had observed.
Very similar observations were made by Cogoli-Greuter et al. (1979) , who observed a pyruvate-induced inactivation of yeast pyruvate decarboxylase only in the presence of dichlorophenolindophenol. This inactivation was also not reversed by gel filtration or by the addition of mercaptoethanol or hydroxylamine. They also observed that a novel TPP derivative had been produced which appeared to be more tightly bound than TPP.
From these results on pyruvate: ferredoxin oxidoreductase, pyruvate dehydrogenase complex and its El component and on yeast pyruvate decarboxylase, a common mechanism can be proposed (Scheme 1). In general, inactivation of the pyruvatedecarboxylating activity is not associated with covalent incorporation of portions of the pyruvate molecule (though incorporation can occur), and it is not reversed by hydroxylamine or dithiothreitol, suggesting that the inactivation is not due to acetylation of essential groups, as proposed by Khailova et al. (1985) . The increase in A235 observed by Khailova et al. (1985) and which was attributed to formation of a thioester bond can be (Gutowski & Lienhard, 1976) , or an equivalent tightly bound inhibitory species. Modification of thiols would then be a secondary reaction independent of the inactivation. Dithiothreitol presumably prevents inactivation either by preventing oxidation of hydroxyethyl-TPP or by reacting with the reactive oxidized species. The exact mechanism by which thiamin thiazolone pyrophosphate is formed is unclear, but could involve attack of peroxide. A simple explanation for the inability of the pyruvate: ferredoxin oxidoreductase to be inhibited by bromopyruvate might be that no suitably placed nucleophile is available, whereas in the pyruvate dehydrogenase complex a thiol (albeit not essential for the mechanism) is present (Lowe & Perham, 1984) . As yet, we have no definitive explanation for the lag phase observed after preincubation of pyruvate: ferredoxin oxidoreductase with bromopyruvate, but possibly bromopyruvate binds at the active site and reacts in situ with CoA to form an adduct which is a potent inhibitor, thus giving stoicheiometric inhibition of enzyme activity. However, the inhibitor could be slowly displaced by the combination of CoA and pyruvate present in the medium, and a steady-state linear inhibited rate would then be obtained. However, this would not explain satisfactorily why addition of pre-formed (unpurified) adduct should also give a lag phase, unless there was sufficient free bromopyruvate still present in the adduct-containing mixture to allow rapid reaction at the active site. In view of the extreme potency of inhibition by bromopyruvate (Table 3) , this possibility is quite likely, and indeed we would have been unable to detect such low amounts of bromopyruvate in the mixture.
Hydroxypyruvate was not an irreversible inhibitor of the El component of pyruvate dehydrogenase complex (Lowe & Perham, 1984) , but was a potent inhibitor of pyruvate: ferredoxin oxidoreductase. Bisswanger (1981) reported irreversible inhibition of E. coli complex by hydroxypyruvate. Possibly this apparent discrepancy is due to a reaction with the lipoic acid groups of the complex, rather than an effect on the El component itself (cf. bromopyruvate; Lowe & Perham, 1984) .
We presume that in the presence of CoA the carbanion intermediate produced after decarboxylation of hydroxypyruvate by pyruvate: ferredoxin oxidoreductase reacts rapidly with CoA and is released from the enzyme (reaction 7, Scheme 1). We propose that, in the absence of CoA, two competing reactions, inactivation or turnover can occur (reactions 4 or 5, Scheme 1). Turnover could result in a decrease in the concentration of the inhibitor, and might account for the curvature of the semi-log plots (Fig. 4) (Kerscher & Oesterhelt, 198 
lb).
We believe that the reason for the lack of effect on pyruvate: ferredoxin oxidoreductase by TPP analogues might be due to the extremely low off-rate of TPP from the enzyme, as witnessed by the observation that this enzyme retains TPP during the purification procedure (Williams et al., 1987) , which is performed in the absence of TPP. In contrast, pyruvate dehydrogenase complex does not retain stoicheiometric amounts of TPP. The extremely tight binding of TPP to the oxidoreductase suggests an alternative hypothesis for the different effects of hydroxypyruvate and bromopyruvate. Possibly hydroxypyruvate is not a truly irreversible inhibitor, but forms a tightly bound dihydroxyethyl-TPP adduct in situ in the active site. Elimination of hydroxide is slow, and hence the adduct is stable. Inhibition of pyruvate dehydrogenase complex does not occur, since the TPP adduct is not so tightly bound. In contrast, bromopyruvate eliminates bromide more readily, and turnover via acetyl-TPP to regenerate TPP occurs efficiently on pyruvate: ferredoxin oxidoreductase. The partitioning to form an enzyme-nucleophile adduct is low on this enzyme, whereas on pyruvate dehydrogenase complex irreversible inhibition, by reaction with an enzyme thiol, occurs once in every 100 turnovers (Lowe & Perham, 1984 
